Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Corvol J-C, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques A-R, Bourdain F, Brandel J-P, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee P-C, Brice A, Vidailhet M, Elbaz A, for the DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91:e189-201. [Ref.ID 102695]
2.Tiene citas relacionadas Cita con resumen
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas Ch, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Valle N, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 0;383:1138-46. [Ref.ID 97374]
3. Cita con resumen
Pérez-Llobet S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc J-L, Rascol O. Do Parkinson's disease patients disclose their adverse events spontaneously?. Eur J Clin Pharmacol 2012;68:857-65. [Ref.ID 92830]
4.Tiene citas relacionadas
Olanow CW, Rascol O. Rasagiline in Parkinson's disease. The authors reply. N Engl J Med 2010;362:658-9. [Ref.ID 87903]
5.Tiene citas relacionadas Cita con resumen
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78. [Ref.ID 86821]
7. Cita con resumen
Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98. [Ref.ID 61553]
8.Tiene citas relacionadas
Ferreira J, Galitzky M, Montastruc J-L, Rascol O. Sleep attacks in Parkinson's disease. Authors' reply. Lancet 2000;356:598. [Ref.ID 53710]
9.Tiene citas relacionadas
Rascol O. Ropinirole as compared with levodopa in Parkinson's disease. Dr. Rascol replies. N Engl J Med 2000;343:885. [Ref.ID 52812]
10. Cita con resumen
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91. [Ref.ID 50999]
11.Tiene citas relacionadas Cita con resumen
Ferreira JJ, Galitzky M, Montastruc J-L, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000;355:1333-4. [Ref.ID 50453]
12. Cita con resumen
Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Eur J Clin Pharmacol 1999;55:299-303. [Ref.ID 45318]
13. Cita con resumen
Llau M-E, Senard JM, Rascol O, Montastruc J-L. Mouvements anormaux d'origine médicamenteuse: l'expérience d'un centre de pharmacovigilance sur cinq ans. Therapie 1995;50:425-7. [Ref.ID 25181]
14.
Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc J-L. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs 1995;50:777-91. [Ref.ID 25086]
15. Cita con resumen
Llau M-E, Nguyen L, Senard JM, Rascol O, Montastruc J-L. Syndromes parkinsoniens médicamenteux: dix ans de pharmacovigilance. Therapie 1994;49:459-60. [Ref.ID 23058]
16.
Montastruc J-L, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-93. [Ref.ID 19968]
17.
Montastruc J-L, Rascol O. Traiter la maladie de Parkinson en 1992. Prescrire 1992;12:361-7. [Ref.ID 17918]
18.
Rascol A, Montastruc J-L, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986;26:83-5. [Ref.ID 10832]
Seleccionar todas
 
 1 a 18 de 18